Clinical Trial Update: A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating itacitinib for chronic graft-versus-host disease was terminated, with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Itacitinib (itacitinib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Chronic Graft-versus-host-disease | Phase 2 | Status: TERMINATED | Results posted: 2024-11-06